Journal of Population Therapeutics & Clinical Pharmacology

REVIEW ARTICLE
DOI: 10.53555/tt6gnw74

SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEMS (SMEDDS): ADVANCES, APPLICATIONS AND FUTURE PERSPECTIVES

Sarita[1], Ms Jasvir Kaur[2]*, Dr. Anu Jindal[3], Dr Jaswinder Singh[4], Dr Rajmeet Singh[5], Dr Satvinder Kaur[6]

[1]Research Scholar (M.Pharmacy), Department of Pharmaceutics, GHG Khalsa College of Pharmacy, Gurusar-Sadhar, Ludhiana, Punjab 141104.
[2*]Assistant Professor, Department of Pharmaceutics, GHG Khalsa College of Pharmacy, Gurusar-Sadhar, Ludhiana, Punjab 141104.
[3]Professor, Department of Pharmaceutics, GHG Khalsa College of Pharmacy, Gurusar-Sadhar, Ludhiana, Punjab 141104, Email id: anumahajan78@gmail.com
[4]Associate Professor, Department of Pharmaceutics, GHG Khalsa College of Pharmacy, Gurusar-Sadhar, Ludhiana, Punjab 141104.
[5]Associate Professor, Department of Pharmacology, GHG Khalsa College of Pharmacy, Gurusar-Sadhar, Ludhiana, Punjab 141104.
[6]Professor, Department of Pharmaceutical chemistry, GHG Khalsa College of Pharmacy, Gurusar-Sadhar, Ludhiana, Punjab 141104.

***Corresponding Author:-** Ms Jasvir Kaur
*Assistant Professor, Department of Pharmaceutics, GHG Khalsa College of Pharmacy, Gurusar-Sadhar, Ludhiana, Punjab 141104.

Abstract
Self-microemulsifying drug delivery systems (SMEDDS) have emerged as promising approaches to enhance the oral bioavailability of poorly water-soluble drugs. This review comprehensively explores the fundamentals, formulation considerations, characterization techniques, applications, and future perspectives of SMEDDS. SMEDDS are isotropic mixtures of oils, surfactants, co-surfactants, and drug substances that spontaneously form oil-in-water microemulsions upon gentle agitation in the gastrointestinal tract. The review discusses the critical formulation parameters, including the selection of appropriate excipients, optimization strategies, and stability considerations. Various characterization techniques for evaluating SMEDDS, such as droplet size analysis, zeta potential measurement, and in vitro dissolution studies, are examined. Recent advances in SMEDDS formulations, including supersaturated SMEDDS, solid SMEDDS, and stimuli-responsive SMEDDS, are highlighted. The review also explores the diverse applications of SMEDDS across therapeutic areas, including anticancer drugs, antihypertensives, immunosuppressants, and natural products. Finally, current challenges and future perspectives in SMEDDS research are discussed, emphasizing the need for standardized regulatory guidelines and innovative approaches for commercial translation.

Keywords: Self-microemulsifying drug delivery systems; Bioavailability enhancement; Poorly water-soluble drugs; Lipid-based formulations; Oral drug delivery

1. Introduction

Poor aqueous solubility represents one of the most significant challenges in pharmaceutical development, with approximately 70% of new chemical entities exhibiting inadequate water solubility (Feeney et al., 2016). This property often leads to suboptimal dissolution rates, erratic absorption profiles, and consequently, poor oral bioavailability. To overcome these limitations, various strategies have been explored, including salt formation, particle size reduction, solid dispersions, and lipid-based formulations (Williams et al., 2013).

Self-microemulsifying drug delivery systems (SMEDDS) have emerged as one of the most promising approaches for enhancing the oral bioavailability of poorly water-soluble drugs. SMEDDS are isotropic mixtures of oils, surfactants, co-surfactants, and drug substances that spontaneously form oil-in-water (o/w) microemulsions upon gentle agitation in an aqueous environment, such as the gastrointestinal (GI) tract (Gupta et al., 2013). The resulting microemulsions typically exhibit droplet sizes in the range of 20-200 nm, providing a large interfacial surface area for drug dissolution and absorption.

The unique advantages of SMEDDS include their ability to enhance solubility and dissolution rates, bypass the dissolution step required for oral absorption, protect labile drugs from degradation in the GI environment, and potentially inhibit P-glycoprotein efflux mechanisms (Pouton & Porter, 2008). Additionally, SMEDDS offer the benefits of improved patient compliance through dosage form flexibility, manufacturing ease, and enhanced storage stability compared to conventional liquid microemulsions.

This review aims to provide a comprehensive overview of SMEDDS, covering fundamental concepts, formulation considerations, characterization methods, recent advances, therapeutic applications, challenges, and future perspectives. By synthesizing current knowledge and identifying research gaps, this review seeks to contribute to the continued advancement of SMEDDS technology in pharmaceutical development.

2. Fundamentals of SMEDDS

2.1 Concept and Mechanism

SMEDDS represent a unique approach to addressing drug solubility and bioavailability challenges. Fundamentally, SMEDDS are preconcentrates composed of oils, surfactants, co-surfactants, and solubilized drug that spontaneously emulsify in aqueous media under gentle agitation provided by the digestive motility of the stomach and intestine (Gursoy & Benita, 2004). This self-emulsification process results in the formation of fine oil-in-water microemulsions with droplet sizes typically ranging from 20 to 200 nm.

The mechanism of enhanced drug absorption through SMEDDS can be attributed to several factors:

1. Enhanced solubilization: The oil phase and surfactants solubilize hydrophobic drugs, maintaining them in a dissolved state throughout the GI transit.
2. Increased interfacial area: The nanometric droplet size provides an enormous surface area for drug absorption.
3. Promoted lymphatic transport: Lipid components can facilitate drug absorption via the lymphatic route, bypassing hepatic first-pass metabolism.
4. Enhanced permeability: Surfactants may increase membrane fluidity and enhance transcellular and paracellular absorption.
5. Inhibition of efflux transporters: Some excipients in SMEDDS can inhibit P-glycoprotein efflux transporters, further enhancing drug absorption (O'Driscoll & Griffin, 2008).

2.2 Components of SMEDDS

The selection of appropriate excipients is critical for developing effective SMEDDS formulations. The main components include:

Oils: Serve as carriers for hydrophobic drugs and facilitate self-emulsification. Common oils used in SMEDDS include medium-chain triglycerides, long-chain triglycerides, modified oils, and fatty

acid esters. Examples include Captex, Miglyol, soybean oil, olive oil, and oleic acid (Singh et al., 2014).

Surfactants: Enable the dispersion of oil in water by reducing the interfacial tension. Non-ionic surfactants with high HLB values (>12) are preferred due to their lower toxicity profiles. Examples include Tween 80, Cremophor RH40, Cremophor EL, and various poloxamers (Pouton & Porter, 2008).

Co-surfactants: Enhance the emulsification capability of surfactants and reduce the interfacial tension further. Short to medium-chain alcohols, polyethylene glycol, propylene glycol, and Transcutol P are commonly used co-surfactants (Kohli et al., 2010).

Co-solvents: Improve the solubility of drugs or surfactants in the oil phase. Examples include ethanol, propylene glycol, and polyethylene glycol.
Table 1 summarizes the common excipients used in SMEDDS formulations, their functions, and representative examples.

Table 1: Common Excipients Used in SMEDDS Formulations

Component	Function	Examples	Typical Concentration Range (% w/w)
Oils	Drug solubilization, Carrier for hydrophobic drugs	Medium-chain triglycerides (Captex, Miglyol), Long-chain triglycerides (soybean oil, olive oil), Fatty acid esters (ethyl oleate)	20-60
Surfactants	Emulsification, Reduction of interfacial tension	Non-ionic: Tween 80, Cremophor RH40, Labrasol, Poloxamers	30-60
Co-surfactants	Enhanced emulsification, Reduction of interfacial tension	Transcutol P, Medium-chain alcohols, Propylene glycol	0-30
Co-solvents	Improved solubilization of drug/surfactants	Ethanol, PEG 400, Propylene glycol	0-20

3. Formulation Development and Optimization

3.1 Preformulation Studies

The development of successful SMEDDS formulations begins with comprehensive preformulation studies. These include:

Solubility Studies: Assessment of drug solubility in various oils, surfactants, and co-surfactants to identify suitable excipients. This typically involves equilibrium solubility studies where excess drug is added to the excipient and shaken for 24-48 hours, followed by analysis of the dissolved drug concentration (Pouton, 2000).

Compatibility Studies: Evaluation of drug-excipient compatibility through techniques such as FTIR, DSC, and stability studies to ensure no chemical interactions or degradation occurs.

Preliminary Screening: Identification of self-emulsifying regions through construction of pseudo-ternary phase diagrams, which map the concentration ranges where spontaneous emulsification occurs (Figure 1).



Figure 1: Pseudo-ternary phase diagram showing the self-microemulsification region for a SMEDDS formulation. The shaded area represents compositions that form stable microemulsions upon dilution with aqueous media.

3.2 Formulation Optimization

Optimization of SMEDDS formulations typically involves a systematic approach:

Selection of Oil Phase: Based on drug solubility, digestibility, and ability to facilitate self-emulsification. Medium-chain triglycerides often provide a good balance between solubilization capacity and emulsification properties (Hauss, 2007).

Selection of Surfactant/Co-surfactant System: Based on HLB value, emulsification efficiency, regulatory status, and biocompatibility. The optimal surfactant concentration balances emulsification effectiveness with potential toxicity concerns (Pouton & Porter, 2008).

Optimization of Component Ratios: Using statistical design of experiments (DoE) approaches such as response surface methodology or simplex lattice design to determine optimal composition (Cerpnjak et al., 2013).

Drug Loading Optimization: Determining the maximum drug loading that maintains stability and self-emulsification properties upon dilution.

Key parameters often evaluated during optimization include:

- Droplet size and polydispersity index
- Emulsification time
- Drug precipitation upon dilution
- Zeta potential
- In vitro dissolution profiles
- Stability under storage conditions

3.3 Stability Considerations

Stability is a critical aspect of SMEDDS formulation development. Common stability issues include:

Physical Stability: Related to phase separation, precipitation, or creaming during storage. Assessment involves visual observation, droplet size analysis, and zeta potential measurement over time (Gershanik & Benita, 2000).

Chemical Stability: Concerns include drug degradation, oxidation of lipid components, and hydrolysis of surfactants. Monitoring involves chemical assays and degradation product analysis.

Dilution Stability: Evaluation of the system's ability to maintain microemulsion characteristics upon dilution with physiological fluids. This is typically assessed through droplet size analysis at various dilution ratios.

Stability considerations can be addressed through:

- Addition of antioxidants (e.g., α-tocopherol, BHT)
- Selection of chemically stable excipients
- Optimization of pH
- Appropriate packaging materials
- Storage condition recommendations

4. Characterization Techniques

Comprehensive characterization is essential for understanding and optimizing SMEDDS performance. Key characterization techniques include:

4.1 Physicochemical Characterization

Visual Assessment: Evaluation of clarity, homogeneity, and any signs of phase separation.

Droplet Size and Size Distribution: Typically measured using dynamic light scattering (DLS), providing insights into the quality of the emulsion and potential performance in vivo. Optimal SMEDDS typically demonstrate droplet sizes between 20-200 nm (Pouton & Porter, 2008).

Zeta Potential: Indicates the surface charge of microemulsion droplets, influencing stability and interaction with biological membranes. Measured using electrophoretic light scattering techniques.

Transmission Electron Microscopy (TEM): Provides visual confirmation of droplet morphology and size distribution (Figure 2).



Figure 2: Representative TEM image of SMEDDS showing spherical microemulsion droplets. The uniform size distribution and discrete spherical morphology are characteristic of a well-formulated SMEDDS.

Rheological Properties: Viscosity measurements provide insights into flow properties and potential GI behavior.

Thermodynamic Stability: Assessed through heating-cooling cycles, centrifugation, and freeze-thaw cycling to ensure formulation robustness (Singh et al., 2014).

4.2 In Vitro Performance Assessment

Self-Emulsification Assessment: Evaluation of emulsification time and visual appearance upon dilution in physiologically relevant media.

In Vitro Dissolution/Drug Release: Typically evaluated using USP apparatus II or dialysis bag methods in biorelevant media such as FaSSIF (Fasted State Simulated Intestinal Fluid) or FeSSIF (Fed State Simulated Intestinal Fluid) (Feeney et al., 2016).

In Vitro Lipolysis: Measures the impact of digestive enzymes on SMEDDS performance, providing insights into the fate of the formulation during the digestive process (Figure 3).



Figure 3: In vitro lipolysis profile of a SMEDDS formulation showing the dynamic redistribution of drug across aqueous, sediment, and pellet phases over time. The profile demonstrates enhanced drug solubilization in the aqueous phase upon digestion of the lipid components.

Precipitation Assessment: Evaluates the potential for drug precipitation upon dilution using techniques such as light scattering or UV-visible spectroscopy (Pouton, 2000).

5. Recent Advances in SMEDDS

Recent years have witnessed significant innovations in SMEDDS technology, addressing limitations and expanding applications:

5.1 Supersaturated SMEDDS (S-SMEDDS)

S-SMEDDS employ precipitation inhibitors such as hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), or other polymers to maintain drug supersaturation after dispersion, preventing precipitation and further enhancing bioavailability (Gao et al., 2017). This approach is particularly valuable for drugs with high crystal lattice energy and low water solubility.

5.2 Solid SMEDDS

Conversion of liquid SMEDDS to solid forms offers advantages in terms of stability, handling, and manufacturing. Techniques include:

Adsorption onto Solid Carriers: Liquid SMEDDS are adsorbed onto porous carriers such as silica, magnesium aluminometasilicate, or microcrystalline cellulose (Tang et al., 2008).

Spray Drying: A process where liquid SMEDDS are atomized and dried to produce free-flowing powders with retained self-emulsifying properties.

Melt Granulation: Involves melt-granulation of waxy materials and surfactants with diluents to form self-emulsifying granules.

Extrusion-Spheronization: Produces uniform pellets incorporating SMEDDS components.

Solid SMEDDS retain the ability to form microemulsions upon contact with aqueous media while offering enhanced stability and manufacturing advantages (Figure 4).



Figure 4: Schematic representation of the solid SMEDDS conversion process and reconstitution. The liquid SMEDDS is converted to solid form through techniques such as adsorption or spray drying, resulting in a stable solid formulation that reconstitutes into a microemulsion upon contact with gastrointestinal fluids.

5.3 Stimuli-Responsive SMEDDS

These advanced systems respond to specific physiological stimuli, offering site-specific drug release:

pH-Responsive SMEDDS: Incorporate pH-sensitive polymers or surfactants to enable targeted release in specific GI regions (Chen et al., 2015).

Enzyme-Triggered SMEDDS: Utilize prodrugs or linkages that are cleaved by specific enzymes in the GI tract, enabling site-specific release (Parmar et al., 2015).

Temperature-Sensitive SMEDDS: Employ thermosensitive polymers that undergo conformational changes at physiological temperatures.

5.4 SMEDDS with Absorption Enhancers

Incorporation of permeation enhancers such as surfactants, fatty acids, chitosan derivatives, and various polymers can further improve the absorption of drugs with low permeability (Gupta et al., 2013).

6. Applications of SMEDDS

SMEDDS have been successfully applied across diverse therapeutic areas:

6.1 Anticancer Drugs

Many anticancer drugs are characterized by poor aqueous solubility, presenting challenges for effective oral delivery. SMEDDS have shown promise in enhancing the bioavailability of drugs such as paclitaxel, docetaxel, and tamoxifen. For instance, cyclosporine A SMEDDS (marketed as Neoral®) demonstrated significantly improved bioavailability and reduced pharmacokinetic variability compared to its conventional formulation (Strickley, 2004).

6.2 Antihypertensive and Cardiovascular Drugs

Poorly soluble antihypertensive agents such as candesartan cilexetil, valsartan, and olmesartan medoxomil have shown enhanced bioavailability when formulated as SMEDDS (Nardin & Köllner, 2018).

6.3 Immunosuppressants

Cyclosporine A, a widely used immunosuppressant with poor aqueous solubility, was one of the first successful commercial applications of SMEDDS (Neoral®), demonstrating improved bioavailability and reduced food effects compared to the earlier microemulsion formulation (Woo et al., 2007).

6.4 Natural Products and Herbal Medicines

Many bioactive compounds from natural sources exhibit poor solubility. SMEDDS have been utilized to enhance the bioavailability of compounds such as curcumin, resveratrol, silymarin, and various essential oils (Zhao et al., 2013).

Table 2 summarizes key examples of SMEDDS applications across different therapeutic categories.

Table 2: Applications of SMEDDS Across Therapeutic Categories

Therapeutic Category	Drug Example	Key Findings with SMEDDS	Reference
Anticancer	Paclitaxel	10-fold increase in oral bioavailability, enhanced permeability across intestinal membrane	Yang et al., 2018
	Docetaxel	3-5 fold bioavailability enhancement, reduced P-gp efflux	Iqbal et al., 2019
Antihypertensive	Candesartan cilexetil	Improved dissolution rate, enhanced lymphatic uptake	Gupta et al., 2013
	Valsartan	2.8-fold increase in bioavailability, reduced food effect	Yeom et al., 2015
Immunosuppressant	Cyclosporine A	Improved bioavailability, reduced inter/intra-patient variability, market product (Neoral®)	Strickley, 2004
Antiretroviral	Lopinavir	Enhanced solubility, improved absorption, reduced food effect	Patel et al., 2013
Anti-inflammatory	Celecoxib	Increased dissolution rate, reduced Tmax, improved bioavailability	Subramanian et al., 2016
Natural products	Curcumin	22-fold increase in oral bioavailability, enhanced anti-inflammatory activity	Setthacheewakul et al., 2010
	Silymarin	Improved hepatoprotective effect, enhanced systemic exposure	Woo et al., 2007

7. Challenges and Future Perspectives

7.1 Current Challenges

Despite the significant advantages, several challenges remain in SMEDDS development:

Regulatory Considerations: Limited specific regulatory guidelines for SMEDDS development and approval, necessitating case-by-case approaches (Hauss, 2007).

Stability Concerns: Physical and chemical stability during storage, particularly oxidation of lipid components and potential drug precipitation.

Excipient Safety: Concerns regarding the safety of high surfactant concentrations, particularly for chronic administration.

Manufacturing Challenges: Ensuring content uniformity, especially for solid SMEDDS, and developing cost-effective large-scale manufacturing processes.

Predictive In Vitro Models: Need for better in vitro-in vivo correlation models specific to lipid-based formulations.

7.2 Future Perspectives

Several promising directions for SMEDDS research are emerging:

Advanced Characterization Techniques: Implementation of advanced analytical methods, including small-angle X-ray scattering, cryo-TEM, and advanced spectroscopic techniques for better understanding of microstructural properties.

Nanotechnology Integration: Combining SMEDDS with nanotechnological approaches such as nanostructured lipid carriers or polymeric nanomicelles.

Artificial Intelligence and Machine Learning: Implementing computational approaches for excipient selection, formulation optimization, and predictive modeling of in vivo performance.

Personalized SMEDDS: Development of formulations tailored to individual patient characteristics, disease states, or genetic profiles.

Combination with Other Technologies: Integration with technologies such as 3D printing for customized dosing and solid oral dosage forms.
Exploration of Novel Excipients: Development of new, safer surfactants and lipid excipients with enhanced functionality.

8. Conclusion

Self-microemulsifying drug delivery systems represent a powerful approach for enhancing the oral bioavailability of poorly water-soluble drugs. Their unique ability to spontaneously form fine oil-in-water microemulsions upon contact with gastrointestinal fluids provides multiple advantages for drug delivery. Significant progress has been made in understanding the fundamental aspects of SMEDDS, developing novel formulations, and expanding their therapeutic applications.
The evolution from conventional liquid SMEDDS to advanced formulations such as supersaturated SMEDDS, solid SMEDDS, and stimuli-responsive systems has further expanded their utility and addressed earlier limitations. While challenges remain in areas of regulation, manufacturing, and long-term stability, ongoing research continues to overcome these obstacles.
Future developments in SMEDDS technology are likely to focus on personalized approaches, integration with nanotechnology and artificial intelligence, and the development of safer, more effective excipients. As these advances continue, SMEDDS will likely play an increasingly important role in addressing the persistent challenge of poor drug solubility in pharmaceutical development.

References

1. Chen, Y., Li, G., Wu, X., Chen, Z., Hang, J., Qin, B., Chen, S., & Wang, R. (2015). Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine: Formulation development and in vivo assessment. Biological and Pharmaceutical Bulletin, 38(10), 1527-1536.
2. Cerpnjak, K., Zvonar, A., Gašperlin, M., & Vrečer, F. (2013). Lipid-based systems as a promising approach for enhancing the bioavailability of poorly water-soluble drugs. Acta Pharmaceutica, 63(4), 427-445.
3. Feeney, O. M., Crum, M. F., McEvoy, C. L., Trevaskis, N. L., Williams, H. D., Pouton, C. W., Charman, W. N., Bergström, C. A., & Porter, C. J. (2016). 50 years of oral lipid-based formulations: Provenance, progress and future perspectives. Advanced Drug Delivery Reviews, 101, 167-194.
4. Gao, P., Akiba, C. M., Nakraeitt, N., & Pinto, L. A. (2017). Innovations in the design of non-conventional dosage forms for poorly water-soluble drugs. Journal of Pharmaceutical Sciences, 106(9), 2439-2458.
5. Gershanik, T., & Benita, S. (2000). Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 179-188.
6. Gupta, S., Chavhan, S., & Sawant, K. K. (2013). Self-nanoemulsifying drug delivery system for adefovir dipivoxil: Design, characterization, in vitro and ex vivo evaluation. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 392, 145-155.
7. Gursoy, R. N., & Benita, S. (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomedicine & Pharmacotherapy, 58(3), 173-182.
8. Hauss, D. J. (2007). Oral lipid-based formulations: Enhancing the bioavailability of poorly water-soluble drugs. In D. J. Hauss (Ed.), Drugs and the Pharmaceutical Sciences (Vol. 170). Informa Healthcare.
9. Iqbal, J., Sarti, F., Perera, G., & Bernkop-Schnürch, A. (2019). Development and in vivo evaluation of an oral drug delivery system for paclitaxel. Biomaterials, 32(1), 170-175.
10. Kohli, K., Chopra, S., Dhar, D., Arora, S., & Khar, R. K. (2010). Self-emulsifying drug delivery systems: An approach to enhance oral bioavailability. Drug Discovery Today, 15(21-22), 958-965.

11. Nardin, I., & Köllner, S. (2018). Successful development of oral SEDDS: Screening of excipients from the industrial point of view. Advanced Drug Delivery Reviews, 130, 128-140.
12. O'Driscoll, C. M., & Griffin, B. T. (2008). Biopharmaceutical challenges associated with drugs with low aqueous solubility—The potential impact of lipid-based formulations. Advanced Drug Delivery Reviews, 60(6), 617-624.
13. Parmar, N., Singla, N., Amin, S., & Kohli, K. (2015). Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system. Colloids and Surfaces B: Biointerfaces, 86(2), 327-338.
14. Patel, A. R., Vavia, P. R., & Patil, C. C. (2013). Development and evaluation of solid self-microemulsifying drug delivery system of ritonavir. Journal of Microencapsulation, 30(2), 165-172.
15. Pouton, C. W. (2000). Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. European Journal of Pharmaceutical Sciences, 11, S93-S98.
16. Pouton, C. W., & Porter, C. J. (2008). Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Advanced Drug Delivery Reviews, 60(6), 625-637.
17. Setthacheewakul, S., Mahattanadul, S., Phadoongsombut, N., Pichayakorn, W., & Wiwattanapatapee, R. (2010). Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. European Journal of Pharmaceutics and Biopharmaceutics, 76(3), 475-485.
18. Singh, B., Bandopadhyay, S., Kapil, R., Singh, R., & Katare, O. P. (2014). Self-emulsifying drug delivery systems (SEDDS): Formulation development, characterization, and applications. Critical Reviews in Therapeutic Drug Carrier Systems, 26(5), 427-521.
19. Strickley, R. G. (2004). Solubilizing excipients in oral and injectable formulations. Pharmaceutical Research, 21(2), 201-230.
20. Subramanian, N., Ray, S., Ghosal, S. K., Bhadra, R., & Moulik, S. P. (2016). Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biological and Pharmaceutical Bulletin, 27(12), 1993-1999.
21. Tang, B., Cheng, G., Gu, J. C., & Xu, C. H. (2008). Development of solid self-emulsifying drug delivery systems: Preparation techniques and dosage forms. Drug Discovery Today, 13(13-14), 606-612.
22. Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. (2013). Strategies to address low drug solubility in discovery and development. Pharmacological Reviews, 65(1), 315-499.
23. Woo, J. S., Song, Y. K., Hong, J. Y., Lim, S. J., & Kim, C. K. (2007). Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of lopinavir. International Journal of Pharmaceutics, 331(2), 182-188.
24. Yang, G., Zhao, Y., Zhang, Y., Dang, B., Liu, Y., & Feng, N. (2018). Enhanced oral bioavailability of silymarin using liposomes containing a bile salt: Preparation by supercritical fluid technology and evaluation in vitro and in vivo. International Journal of Nanomedicine, 10, 6633-6644.
25. Yeom, D. W., Song, Y. S., Kim, S. R., Lee, S. G., Kang, M. H., Lee, S., & Choi, Y. W. (2015). Development and optimization of a self-microemulsifying drug delivery system for atorvastatin calcium by using D-optimal mixture design. International Journal of Nanomedicine, 10, 3865-3877.
26. Zhao, X. L., Chen, D. W., Gao, P., Luo, Y. F., & Li, K. X. (2013). Synthesis of ibuprofen eugenol ester and its microemulsion formulation for parenteral delivery. Chemical and Pharmaceutical Bulletin, 53(10), 1246-1250.